(Q34651347)

3 August 2017

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study (English)

1 reference

3 August 2017

Paolo Antonio Ascierto

6

object named as

P A Ascierto

1 reference

3 August 2017

M P Pistillo

12

1 reference

ORCID Public Data File 2021

author name string

P Queirolo

1

1 reference

3 August 2017

A Morabito

2

1 reference

3 August 2017

S Laurent

3

1 reference

3 August 2017

S Lastraioli

4

1 reference

3 August 2017

P Piccioli

5

1 reference

3 August 2017

G Gentilcore

7

1 reference

3 August 2017

M Serra

8

1 reference

3 August 2017

A Marasco

9

1 reference

3 August 2017

E Tornari

10

1 reference

3 August 2017

B Dozin

11

1 reference

3 August 2017

language of work or name

1 reference

3 May 2013

1 reference

3 August 2017

1 reference

3 August 2017

31

1 reference

3 August 2017

5

1 reference

3 August 2017

336-345

1 reference

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

3 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Melanoma drug wins US approval.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products f

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Atypical clinical response patterns to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Genomic regulation of CTLA4 and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Hexaprimer amplification refractory mutation system PCR for simultaneous single-tube genotyping of 2 close polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2013.793699

10.3109/07357907.2013.793699

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference